← Eichor
Condition: Neuroendocrine Tumors Gastroenteropancreatic Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Neuroendocrine Tumors Gastroenteropancreatic

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Cabozantinib and Lanreotide as Treatment for Gastroenteropancreatic Neuroendocrine Tumors
Phase 1/Phase 2 · 11 location(s) · National Health Research Institutes, Taiwan · NCT05048901A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
Phase 1/Phase 2 · 15 location(s) · Phanes Therapeutics · NCT05652686An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancr
Phase 3 · 2 location(s) · Jiangsu HengRui Medicine Co., Ltd. · NCT05884255Nutritional Status Assessment in Adult Patients Followed for Gastroenteropancreatic Neuroendocrine Tumors at Strasbourg
Phase N/A · 1 location(s) · University Hospital, Strasbourg, France · NCT07302100Continuing Somatostatin Analogues Upon Progression in Neuroendocrine Tumour pAtients
Phase 4 · 19 location(s) · University Hospital, Antwerp · NCT05701241Multi-modal Characterisation of Gastroenteropancreatic Neuroendocrine Tumours (GEP-NETs) Treated With Targeted Radionucl
NA · 5 location(s) · Assistance Publique - Hôpitaux de Paris · NCT06256705Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors
Phase 1 · 20 location(s) · SystImmune Inc. · NCT07080242Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.
Phase 1 · 9 location(s) · RayzeBio, Inc. · NCT0716513268Ga-DOTATOC PET for the Evaluation of Gastroenteropancreatic Neuroendocrine Tumours
Phase N/A · 1 location(s) · IRCCS San Raffaele · NCT06155318Tarlatamab vs Standard of Care Chemotherapy in Patients With Pre-treated Advanced, Pulmonary or Gastroenteropancreatic P
Phase 3 · 40 location(s) · Intergroupe Francophone de Cancerologie Thoracique · NCT06937905Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET
Phase 3 · 65 location(s) · Novartis Pharmaceuticals · NCT06784752Study of PRRT in Metastatic, World Health Organization (WHO) Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for
Phase 1 · 1 location(s) · Stanford University · NCT04609592Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroe
Phase 2 · 39 location(s) · National Cancer Institute (NCI) · NCT05773274Evaluating the Safety, Tolerability, and Preliminary Anti-tumor Activity of MB0151 in Adult Subjects With Advanced Solid
Phase 1/Phase 2 · 1 location(s) · Mainline Biosciences (Shanghai) Co., Ltd · NCT06840821Peptide Receptor Radionuclide Therapy (PRRT) for the Treatment of Neuroendocrine Tumors
Phase N/A · 2 location(s) · Methodist Health System · NCT04090034Intra-arterial Hepatic (IAH) Infusion of Radiolabelled Somatostatin Analogs in GEP-NET Patients With Dominant Liver Meta
Phase 2 · 4 location(s) · University Hospital, Bordeaux · NCT04837885Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Sol
Phase 1/Phase 2 · 5 location(s) · Molecular Partners AG · NCT07278479Chemotherapy For Metastatic Grade 3 Poorly Differentiated NEuroendocrine Carcinoma Of GastroEnteroPancreatic And Unknown
Phase 2 · 6 location(s) · Centre Hospitalier Universitaire Dijon · NCT04325425Sirolimus for Injection (Albumin Bound) Combined With Octreotide Long-acting Injection in Patients With Metastatic Gastr
Phase 2/Phase 3 · 1 location(s) · CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · NCT07165886Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 17
Phase 3 · 54 location(s) · RayzeBio, Inc. · NCT05477576Observational Study on GEP-and Pulm-NET Treated at FPG
Phase N/A · 1 location(s) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS · NCT06402695PRRT Versus PRRT Plus Chemotherapy in GEP NET (PReCedeNT Trial)
Phase 3 · 2 location(s) · Tata Memorial Hospital · NCT07185672Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Well Differentiated Gastroenteropancreatic Neuroend
Phase 4 · 1 location(s) · Vanderbilt-Ingram Cancer Center · NCT06016855A Study of Treatment Patterns and Outcomes in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients
Phase N/A · 1 location(s) · Novartis Pharmaceuticals · NCT07635316Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors
Phase 1 · 7 location(s) · Novartis Pharmaceuticals · NCT07006727Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors
Phase 1/Phase 2 · 19 location(s) · Perspective Therapeutics · NCT05636618
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.